BALTIMORE, June 26, 2026 (GLOBE NEWSWIRE) -- Elixirgen Therapeutics, Inc ., a clinical-stage biotechnology company developing treatments for rare diseases and aging-associated diseases, today announced that it has entered into an option agreement with Nippon Shinyaku Co., Ltd. (Headquarters, Kyoto, Japan; President, Toru Nakai). Under the terms of the agreement, Elixirgen will be responsible for the development of EXG-7001 for the treatment of Duchenne Muscular Dystrophy (DMD) and Nippon Shinyak